Jacob Chacko Sells 34,538 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 34,538 shares of the company’s stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $12.01, for a total value of $414,801.38. Following the sale, the chief executive officer owned 621,881 shares in the company, valued at approximately $7,468,790.81. This trade represents a 5.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jacob Chacko also recently made the following trade(s):

• On Wednesday, October 1st, Jacob Chacko sold 53,001 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $12.05, for a total value of $638,662.05.
• On Monday, September 22nd, Jacob Chacko sold 125,000 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $10.80, for a total value of $1,350,000.00.

Oric Pharmaceuticals Stock Up 2.1%

NASDAQ ORIC opened at $11.56 on Friday. Oric Pharmaceuticals, Inc. has a 52 week low of $3.90 and a 52 week high of $14.67. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -6.12 and a beta of 1.68. The company has a fifty day moving average of $10.39 and a two-hundred day moving average of $8.51.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). Equities research analysts anticipate that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Saturday, September 27th. Zacks Research raised Oric Pharmaceuticals to a “hold” rating in a research report on Tuesday, August 12th. Guggenheim initiated coverage on Oric Pharmaceuticals in a research note on Thursday, September 4th. They issued a “buy” rating and a $18.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $20.00 target price on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. Finally, HC Wainwright cut their price target on shares of Oric Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.29.

Institutional Investors Weigh In On Oric Pharmaceuticals

Several large investors have recently modified their holdings of ORIC. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Oric Pharmaceuticals by 2.9% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company’s stock worth $497,000 after buying an additional 1,358 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its holdings in Oric Pharmaceuticals by 35.9% in the second quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company’s stock worth $53,000 after acquiring an additional 1,372 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Oric Pharmaceuticals by 17,300.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,436 shares of the company’s stock worth $25,000 after acquiring an additional 2,422 shares during the last quarter. Ameriprise Financial Inc. grew its stake in shares of Oric Pharmaceuticals by 7.5% during the second quarter. Ameriprise Financial Inc. now owns 38,864 shares of the company’s stock worth $394,000 after acquiring an additional 2,706 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Oric Pharmaceuticals by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after acquiring an additional 3,131 shares in the last quarter. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.